Tanner V, Kanski J J, Frith P A
Oxford Eye Hospital, UK.
Eye (Lond). 1998;12 ( Pt 4):679-85. doi: 10.1038/eye.1998.168.
This is the first study reported in the United Kingdom to investigate the efficacy and safety of posterior, sub-Tenon's triamcinolone acetonide injections in the treatment of posterior and intermediate uveitis.
Twenty-eight posterior sub-Tenon's triamcinolone injections (40 mg) were given and the results analysed with a 6 month prospective follow-up in 13 cases.
At 6 weeks follow-up, objective improvement in visual acuity occurred in 25 eyes (p < 0.05). Vitreous cellular activity was diminished in 21 eyes (p < 0.05). In most cases improvement was observed within 2 weeks of injection. No patient required repeat triamcinolone injection within 3 months and all patients previously treated with systemic immunosuppression were able to decrease or discontinue this treatment. Complications included transient elevation of intraocular pressure in 4 patients and persistent mild ptosis in 2 patients.
We have demonstrated that posterior sub-Tenon's triamcinolone injection significantly decreases cystoid macular oedema, with a corresponding increase in visual acuity, in patients with posterior uveitis. Systemic immunosuppression may be reduced or discontinued with the avoidance of associated systemic side effects, and the technique has a high level of patient acceptability.
这是英国报道的第一项研究，旨在调查后Tenon囊下注射曲安奈德治疗后葡萄膜炎和中间葡萄膜炎的疗效和安全性。
进行了28次后Tenon囊下曲安奈德注射（40毫克），并对13例患者进行了为期6个月的前瞻性随访，分析结果。
在6周的随访中，25只眼的视力有客观改善（p < 0.05）。21只眼的玻璃体细胞活性降低（p < 0.05）。在大多数情况下，注射后2周内观察到改善。3个月内无患者需要重复注射曲安奈德，所有先前接受全身免疫抑制治疗的患者都能够减少或停止这种治疗。并发症包括4例患者眼压短暂升高和2例患者持续性轻度上睑下垂。
我们已经证明，后Tenon囊下注射曲安奈德可显著降低后葡萄膜炎患者的黄斑囊样水肿，并相应提高视力。可减少或停止全身免疫抑制，避免相关的全身副作用，且该技术具有较高的患者接受度。
